M16-126 A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection
Phase of Trial: Phase III
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms M16-126
- Sponsors AbbVie
- 14 Apr 2017 Planned End Date changed from 1 Jul 2018 to 10 Oct 2018.
- 14 Apr 2017 Planned primary completion date changed from 1 Mar 2018 to 18 Jul 2018.
- 02 Feb 2017 Status changed from not yet recruiting to recruiting.